Predicting human drug toxicity and safety via animal tests: Can any one species predict drug toxicity in any other, and do monkeys help?

ATLA Alternatives to Laboratory Animals

Volumn 43, Issue 6, 2015, Pages 393-403

  Bailey, Jarrod ^a   Thew, Michelle ^a   Balls, Michael ^b  

^a Cruelty Free International   (United Kingdom)

^b RUSSELL AND BURCH HOUSE   (United Kingdom)

Author keywords

Animal tests; Dog; Drug development; Monkey; Mouse; Non human primate; Preclinical testing; Rabbit; Rat; Toxicology

Indexed keywords

DRUG;

ADVERSE DRUG REACTION; ARTICLE; DOG; DRUG SAFETY; DRUG TOXICITY; HAPLORHINI; HUMAN; NONHUMAN; PREDICTION; PREDICTIVE VALUE; PRIMATE; PRIORITY JOURNAL; RABBIT; ANIMAL; ANIMAL EXPERIMENT; DRUG SCREENING;

ANIMAL EXPERIMENTATION; ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PRIMATES;

EID: 84956931624     PISSN: 02611929     EISSN: 26323559     Source Type: Journal    
DOI: 10.1177/026119291504300607     Document Type: Article

References (24)

1. Anon. (2004). Directive 2004/27/EC of the Euro-pean Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union L136, 30.04.2004, 34-79.
2. Anon. (2009). The 1938 Food, Drug and Cosmetics Act. Silver Spring, MD, USA: US Food and Drug Administration. Available at: http://www.fda.gov/ AboutFDA/WhatWeDo/History/ProductRegulation/ ucm132818.htm (Accessed 29.10.15).
3. Aithal, G.P. (2010). Mind the gap. ATLA 38, Suppl. 1, 1-4.
4. Duyk, G. (2003). Attrition and translation. Science, New York 302, 603-605.
5. Kola, I. & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3, 711-715.
6. Wehling, M. (2011). Drug development in the light of translational science: Shine or shade? Drug Discovery Today 16, 1076-1083.
7. DiMasi, J.A. (2014). Pharmaceutical R&D performance by firm size: Approval success rates and economic returns. American Journal of Therapeutics 21, 26-34.
8. Bailey, J., Thew, M. & Balls, M. (2013). An analysis of the use of dogs in predicting human toxicology and drug safety. ATLA 41, 335-350.
9. Bailey, J., Thew, M. & Balls, M. (2014). An analysis of the use of animal models in predicting human toxicology and drug safety. ATLA 42, 181-199.
10. Altman, D.G. & Bland, J.M. (1994). Diagnostic tests 2: Predictive values. British Medical Journal 309, 102.
11. Grimes, D.A. & Schulz, K.F. (2005). Refining clinical diagnosis with likelihood ratios. Lancet 365, 1500-1505.
12. McGee, S. (2002). Simplifying likelihood ratios. Journal of General Internal Medicine 17, 646-549.
13. Anon. (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union L276, 20.10.2010, 33-79.
14. Anon. (2010). Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products-March 2004. Silver Spring, MD, USA: US Food and Drug Administration. Available at: http://www.fda.gov/ScienceResearch/ SpecialTopics/CriticalPathInitiative/CriticalPath OpportunitiesReports/ucm077262.htm (Accessed 29.10.15).
15. Issa, A.M., Phillips, K.A., Van Bebber, S., Nida-marthy, H.G., Lasser, K.E., Haas, J.S., Alldredge, B.K., Wachter, R.M. & Bates, D.W. (2007). Drug withdrawals in the United States: A systematic review of the evidence and analysis of trends. Current Drug Safety 2, 177-185.
16. Bennani, Y.L. (2011). Drug discovery in the next decade: Innovation needed ASAP. Drug Discovery Today 16, 779-792.
17. Eichler, H.G., Aronsson, B., Abadie, E. & Salmon-son, T. (2010). New drug approval success rate in Europe in 2009. Nature Reviews Drug Discovery 9, 355-356.
18. Hughes, B. (2008). 2007 FDA drug approvals: A year of flux. Nature Reviews Drug Discovery 7, 107-109.
19. Hartung, T. (2009). Toxicology for the twenty-first century. Nature, London 460, 208-212.
20. Aurup, P. (2012). Er Danmark et Attraktivt Land for Klinisk Forskning? [Is Denmark an Attractive Country for Clinical Research?; Presentation]. Available at: http://di.dk/SiteCollectionDocuments/ Opinion/Sundhed/Høring/Præsentation%20-%20 Peter%20Aurup,%20Merck.pdf (Accessed 29.10.15).
21. Martinez, M.N., Antonovic, L., Court, M., Dacasto, M., Fink-Gremmels, J., Kukanich, B., Locuson, C., Mealey, K., Myers, M.J. & Trepanier, L. (2013). Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metabolism Reviews 45, 218-230.
22. Anon. (2007). Petition to the US Food and Drug Admin istration for Mandatory Use of Non-Animal Methods in the Development and Approval of Drugs and Devices, 6pp. Available at: http://www. alternatives-petition.org/docs/MAP-Executive-Summary.pdf (Accessed 29.10.15).
23. Anon. (2012). The AXLR8 Consortium: Alternative Testing Strategies, Progress Report 2012, 288pp. Berlin, Germany: AXLR8 Administration. Avail-able at: http://www.axlr8.eu/assets/axlr8-progressreport-2012.pdf (Accessed 29.10.15).
24. Anon. (2010). Eurobarometer Survey Shows Public Concern on Animal Testing. London, UK: European Coalition to End Animal Experiments. Available at: http://www.eceae.org/no/category/watchingbrief/ 76/eurobarometer-survey-shows-publicconcern-on-animal-testing (Accessed 29.10.15).